TrialClinical cancer research : an official journal of the American Association for Cancer Research2023

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.

Jaleh Fallah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.